Physician profile
Junia Osier
NPI 1265038558
$784.33
in general payments reported to CMS, 2019-2025
14 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.47 · 2023: $84.09 · 2024: $417 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $310.64 | 2024-2025 | Airsupra, Breztri, Byetta |
| Astellas Pharma US INC | $90.09 | 2024-2025 | Veozah |
| Lilly USA, LLC | $63.84 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $58.75 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $42.19 | 2022-2025 | |
| Novo Nordisk INC | $41.46 | 2022-2024 | Rybelsus, Ozempic |
| Protega Pharmaceutials INC | $31.30 | 2024 | Roxybond |
| Glaxosmithkline, LLC. | $28.98 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $28.97 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $20.62 | 2024 | Gvoke Hypopen |
| Amgen INC. | $19.19 | 2024 | Evenity, Prolia |
| Exact Sciences Corporation | $18.86 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.65 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $13.79 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junia Osier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.